GlassScriptPhysician profile
Kipp Ardoin
NPI 1306027701
$523.34
in general payments reported to CMS, 2019-2025
12 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $104 · 2021: $62.89 · 2023: $20.38 · 2024: $39.92 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $166.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $117.56 | 2019-2021 | |
| Corium, LLC | $85.40 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $75.26 | 2020-2021 | |
| Neos Therapeutics, LP | $48.03 | 2019 | |
| Pfizer INC. | $42.59 | 2020 | |
| Collegium Pharmaceutical, INC. | $35.36 | 2025 | Jornay Pm |
| Sanofi Pasteur INC. | $29.12 | 2019-2025 | |
| Abbvie INC. | $22.04 | 2021 | |
| Aytu Biopharma, INC. | $19.90 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $17.99 | 2024 | Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $15.64 | 2021 | |
| Merck Sharp & Dohme LLC | $14.45 | 2025 | Vaqta, Rotateq, M-M-R II |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kipp Ardoin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.